HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Kelly K Hunt Selected Research

Therapeutics

1/2024Exploring Novel Frontiers: Leveraging STAT3 Signaling for Advanced Cancer Therapeutics.
1/2024ASO Visual Abstract: Axillary Nodal Metastases Conversion and Perioperative Complications with Neoadjuvant Pembrolizumab Therapy in Triple-Negative Breast Cancer.
11/2023Axillary Nodal Metastases Conversion and Perioperative Complications with Neoadjuvant Pembrolizumab Therapy in Triple-Negative Breast Cancer.
11/2023Extremely Low Incidence of Local-Regional Recurrences Observed Among T1-2 N1 (1 or 2 Positive SLNs) Breast Cancer Patients Receiving Upfront Mastectomy Without Completion Axillary Node Dissection.
10/2023Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor-Positive Metastatic Breast Cancers.
10/2023Local Recurrence After Breast-Conserving Therapy in Patients With Multiple Ipsilateral Breast Cancer: Results From ACOSOG Z11102 (Alliance).
4/2023Local-Regional Recurrence After Neoadjuvant Endocrine Therapy: Data from ACOSOG Z1031 (Alliance), a Randomized Phase 2 Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical Stage 2 or 3 Breast Cancer.
4/2023ASO Visual Abstract: Local-Regional Recurrence Following Neoadjuvant Endocrine Therapy - Data from ACOSOG Z1031 (Alliance), a Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical Stage 2-3 Breast Cancer.
1/2023Longitudinal dynamic contrast-enhanced MRI radiomic models for early prediction of response to neoadjuvant systemic therapy in triple-negative breast cancer.
1/2023Sequential Targeting of Retinoblastoma and DNA Synthesis Pathways Is a Therapeutic Strategy for Sarcomas That Can Be Monitored in Real Time.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Kelly K Hunt Research Topics

Disease

248Breast Neoplasms (Breast Cancer)
01/2024 - 01/2002
212Neoplasms (Cancer)
03/2024 - 01/2002
41Neoplasm Metastasis (Metastasis)
01/2024 - 05/2002
28Sarcoma (Soft Tissue Sarcoma)
02/2024 - 09/2002
22Pathologic Complete Response
01/2024 - 01/2002
20Noninfiltrating Intraductal Carcinoma (DCIS)
01/2019 - 11/2002
18Triple Negative Breast Neoplasms
01/2024 - 10/2011
14Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma)
03/2024 - 01/2016
13Carcinoma (Carcinomatosis)
07/2020 - 05/2002
11Disease Progression
10/2023 - 08/2003
10Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor)
01/2023 - 12/2003
9Melanoma (Melanoma, Malignant)
09/2018 - 04/2002
8Lobular Carcinoma
01/2021 - 10/2006
8Leiomyosarcoma
01/2017 - 11/2005
7Lymphoma (Lymphomas)
02/2024 - 11/2004
7Lung Neoplasms (Lung Cancer)
01/2018 - 04/2002
7Necrosis
12/2013 - 05/2004
5Residual Neoplasm
01/2024 - 10/2006
5Genomic Instability
12/2022 - 11/2006
5T-Cell Lymphoma (Lymphoma, T Cell)
01/2022 - 01/2016
5Margins of Excision
12/2018 - 02/2003
5Inflammatory Breast Neoplasms
02/2017 - 07/2007
5Lymphatic Metastasis
04/2016 - 04/2008
5Carcinogenesis
01/2016 - 11/2004
4Lymphadenopathy
03/2024 - 02/2011
4Liposarcoma
02/2024 - 04/2015
4Wounds and Injuries (Trauma)
01/2023 - 05/2004
4Lymphedema (Milroy Disease)
02/2019 - 10/2006
4Infections
08/2014 - 08/2005
4Ductal Carcinoma
06/2009 - 10/2006
3Retroperitoneal liposarcoma
02/2023 - 04/2015
3Pain (Aches)
01/2023 - 11/2009
3Hemangiosarcoma (Angiosarcoma)
01/2021 - 12/2005
3Postoperative Pain
03/2020 - 09/2009

Drug/Important Bio-Agent (IBA)

41Estrogen ReceptorsIBA
01/2024 - 10/2003
22Proteins (Proteins, Gene)FDA Link
01/2016 - 12/2002
20Biomarkers (Surrogate Marker)IBA
10/2023 - 12/2002
20Cyclin EIBA
12/2022 - 08/2005
19Hormones (Hormone)IBA
11/2023 - 08/2005
16Doxorubicin (Adriamycin)FDA LinkGeneric
01/2023 - 01/2002
16Progesterone Receptors (Progesterone Receptor)IBA
08/2018 - 04/2002
10Trastuzumab (Herceptin)FDA Link
12/2013 - 08/2004
8Phosphotransferases (Kinase)IBA
01/2023 - 06/2004
8Biological FactorsIBA
07/2020 - 07/2016
8Paclitaxel (Taxol)FDA LinkGeneric
12/2013 - 04/2002
7Cyclophosphamide (Cytoxan)FDA LinkGeneric
01/2023 - 06/2005
7AnthracyclinesIBA
01/2021 - 08/2002
7Coloring Agents (Dyes)IBA
12/2020 - 02/2004
7Protein Isoforms (Isoforms)IBA
10/2018 - 06/2004
7Estrogens (Estrogen)FDA Link
08/2018 - 04/2002
7Fluorouracil (Carac)FDA LinkGeneric
12/2013 - 06/2005
7Imatinib Mesylate (Gleevec)FDA Link
01/2012 - 12/2003
6palbociclibIBA
10/2023 - 01/2017
6Capsules (Microcapsules)IBA
12/2021 - 01/2016
6human ERBB2 proteinIBA
10/2017 - 06/2005
6eIF-2 Kinase (eIF 2 Kinase)IBA
08/2008 - 04/2002
6iso-sulfan blue (Lymphazurin)FDA LinkGeneric
04/2006 - 01/2003
6Double-Stranded RNA (RNA, Double Stranded)IBA
11/2005 - 04/2002
5Phenobarbital (Luminal)FDA Link
01/2024 - 12/2010
5DNA (Deoxyribonucleic Acid)IBA
01/2023 - 11/2006
5ElafinIBA
06/2015 - 12/2007
5TamoxifenFDA LinkGeneric
08/2010 - 01/2002
5CytokinesIBA
02/2007 - 05/2002
4Letrozole (Femara)FDA LinkGeneric
04/2023 - 02/2010
4Aromatase InhibitorsIBA
04/2023 - 02/2010
4taxaneIBA
01/2021 - 12/2009
4Taxoids (Taxanes)IBA
01/2021 - 10/2008
4Cytostatic AgentsIBA
01/2020 - 09/2010
4Epirubicin (Ellence)FDA LinkGeneric
12/2013 - 06/2005
4ParaffinIBA
07/2013 - 01/2004
4E2F1 Transcription FactorIBA
03/2010 - 04/2003
3PlasticsIBA
02/2024 - 05/2002
3Immune Checkpoint InhibitorsIBA
02/2024 - 01/2018
3RNA (Ribonucleic Acid)IBA
01/2024 - 01/2018
3Anastrozole (Arimidex)FDA LinkGeneric
01/2024 - 04/2023
3pembrolizumabIBA
01/2024 - 09/2018
3Poly(ADP-ribose) Polymerase InhibitorsIBA
01/2019 - 01/2017
3EnzymesIBA
01/2018 - 10/2009
3ErbB Receptors (EGF Receptor)IBA
10/2016 - 06/2005
3RoscovitineIBA
01/2012 - 10/2008
3Hematoxylin (Haematoxylon)IBA
07/2011 - 04/2005
3Eosine Yellowish-(YS) (Eosin)IBA
07/2011 - 04/2005

Therapy/Procedure

119Therapeutics
01/2024 - 01/2002
91Neoadjuvant Therapy
02/2024 - 01/2002
62Radiotherapy
02/2024 - 04/2002
60Segmental Mastectomy (Lumpectomy)
07/2023 - 03/2002
55Drug Therapy (Chemotherapy)
02/2024 - 04/2002
49Mastectomy (Mammectomy)
11/2023 - 01/2002
32Lymph Node Excision (Lymph Node Dissection)
06/2023 - 01/2003
15Breast Implants (Breast Implant)
03/2024 - 01/2016
11Adjuvant Chemotherapy
11/2023 - 07/2002
11Mammaplasty (Breast Reconstruction)
01/2019 - 05/2002
6Contraindications
01/2022 - 01/2006
6Aftercare (After-Treatment)
04/2021 - 01/2007
6Surgical Instruments (Clip)
01/2019 - 12/2007
6Brachytherapy
01/2019 - 05/2011
6Prophylactic Mastectomy
01/2018 - 10/2006
4Simple Mastectomy
03/2011 - 03/2004
3Operative Surgical Procedures
10/2016 - 03/2003
3Catheters
08/2014 - 02/2004